ArticleJournal of pharmaceutical policy and practice2022
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.
Article in Journal of pharmaceutical policy and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Article
- From medicine price control to deregulation: assessing policy effects on insulin access in Pakistan's private pharmacies.PloS one · 2026Article
- Assessment of pricing, availability, and affordability of essential medicines in a resource-limited setting.Journal of pharmaceutical policy and practice · 2026Article
- Cost of diarrhoea: a household perspective from seven countries in the Global Enteric Multicentre Study (GEMS).BMJ paediatrics open · 2025Article
- Establishing links between drug registers and essential medicines lists.Bulletin of the World Health Organization · 2025Article
- Voluntary information and price sharing database - a scoping review of the pricing and procurement landscape across eight Commonwealth Member States.Journal of pharmaceutical policy and practice · 2025Review
- Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.Frontiers in pharmacology · 2025Article
- Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry.Journal of pharmaceutical policy and practice · 2025Article
- Impact of equivalent units of production on state-controlled unit cost calculation for fair pricing of pharmaceuticals: a scoping review.Journal of pharmaceutical policy and practice · 2025Review
- Building an effective medicines optimisation model: a health system approach.International journal of clinical pharmacy · 2024Article
- Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services.Pharmacy (Basel, Switzerland) · 2024Article
- Developing Nepal's medicines pricing policy: evidence synthesis and stakeholders' consultation.Journal of pharmaceutical policy and practice · 2024Article
- Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors' Participation, and Context.International journal of health policy and management · 2023Article
- Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries.PloS one · 2023Article
- Comparative price analysis of biological medicines: disparities generated by different pricing policies.Frontiers in pharmacology · 2023Article
- Cost of Illness Analysis of Type 2 Diabetes Mellitus: The Findings from a Lower-Middle Income Country.International journal of environmental research and public health · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Equitable access to medicines has played a vital role to improve patient health outcomes and reducing mortality globally. However, it is important to note that medicines pricing is a key determinant in promoting access to medicines. The studies and empirical data have shown that there are wide variations in prices across countries for the same brand of medicines. World Health Organisation (WHO) has provided guidelines to formulate country pharmaceutical pricing policies. However, little is known how these guidelines will be used in the country-specific setting. This commentary provides guiding principles and outlines the basis to form a medicines pricing policy in a low and middle-income country, Pakistan. It discusses the current medicines pricing policy and provides suggestions for future work. The suggested medicines pricing structure and lessons learned in this commentary can also be applied in other low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.